Sterling Bancorp, Inc. filed its current report on Form 8-K with the Securities and Exchange Commission on January 30, 2025, announcing its financial highlights for the quarter and year ended December 31, 2024. The company reported a net income of $1.2 million, or $0.02 per diluted share, for the fourth quarter of 2024, compared to a net loss of $(0.1) million for the third quarter of 2024. For the full year ended December 31, 2024, net income was $2.1 million, or $0.04 per diluted share, compared to $7.4 million for the year ended December 31, 2023.
The financial statement highlighted a fourth-quarter net interest margin of 2.24% and a full-year net interest margin of 2.37%. Nonperforming loans totaled $14.6 million, representing 1.26% of total loans and 0.60% of total assets. The company’s shareholders’ equity stood at $334.0 million at the end of 2024.
The report included detailed balance sheet information, operational metrics, and forward-looking statements cautioning against relying solely on certain projections. Sterling Bancorp emphasized the competitive environment, regulatory factors, and potential uncertainties that could affect future performance. The company’s report is available for review on the Securities and Exchange Commission’s website for further details.
This article was generated by an automated content engine and was reviewed by a human editor prior to publication. For additional information, read Sterling Bancorp’s 8K filing here.
About Sterling Bancorp
Sterling Bancorp, Inc is a unitary thrift holding company. Its wholly owned subsidiary, Sterling Bank and Trust, F.S.B., has primary branch operations in San Francisco and Los Angeles, California and New York City, and a loan production office in Seattle, Washington. Sterling offers a broad range of loan products to the residential and commercial markets, as well as retail and business banking services.
Featured Articles
- Five stocks we like better than Sterling Bancorp
- Using the MarketBeat Dividend Yield Calculator
- How Value Investors Find Undervalued Stocks and Build Wealth
- How to trade using analyst ratings
- Is Tonix Pharmaceuticals the Next Biotech Breakout?
- What Percentage Gainers Tell Investors and Why They Don’t Tell the Whole Story
- DeepSeek Dip: Is the Nuclear Energy Sell-Off a Buying Opportunity